Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$13.81 USD
+1.32 (10.57%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $14.00 +0.19 (1.38%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$13.81 USD
+1.32 (10.57%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $14.00 +0.19 (1.38%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum B VGM
Zacks News
Immunovant, Inc. (IMVT) Down 10.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Emergent Biosolutions (EBS) Down 21.4% Since Last Earnings Report?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for May 17th
by Zacks Equity Research
BIDU, EBS and FRO have been added to the Zacks Rank #5 (Strong Sell) List on May 17, 2023.
ARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal Spray
by Zacks Equity Research
ARS Pharmaceuticals (SPRY) gains as it gets favorable votes from the FDA advisory committee for epinephrine spray to treat severe allergic reactions.
Emergent (EBS) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Emergent (EBS) reports wider-than-expected first-quarter loss. The company updates its 2023 guidance for selected categories.
Emergent Biosolutions (EBS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -89.82% and 15.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stocks' Q1 Earnings on May 9: NVAX, EBS & More
by Kinjel Shah
Let us look at five biotech companies, NVAX, EBS, BLUE, EXEL and NKTR, which are gearing up for their earnings release.
Emergent Biosolutions (EBS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Emergent Biosolutions (EBS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Is ALPS International Sector Dividend Dogs ETF (IDOG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IDOG
Emergent Biosciences (EBS) Surges 28% in a Week: Here's Why
by Zacks Equity Research
Shares of Emergent (EBS) have been rising following the FDA's approval to an OTC version of its Narcan nasal spray.
Emergent's (EBS) Narcan Gets OTC Status for Opioid Overdose
by Zacks Equity Research
Following the FDA approval, Emergent's (EBS) Narcan nasal spray becomes the first OTC product approved for emergency treatment of opioid overdose. This product will be made available by late summer of this year.
Emergent Biosolutions (EBS) Surges 5.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Emergent Biosolutions (EBS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Emergent Biosolutions (EBS) Down 28.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Emergent's (EBS) Q4 Earnings Miss, Sales Beat Estimates
by Zacks Equity Research
Emergent (EBS) reported mixed fourth-quarter 2022 results. While the company significantly misses the mark on earnings, it beat sales estimates.
Wall Street Analysts Believe Emergent Biosolutions (EBS) Could Rally 134.29%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 134.3% upside potential for Emergent Biosolutions (EBS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -196.88% and 7.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Fulcrum Therapeutics, Inc. (FULC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Fulcrum Therapeutics, Inc. (FULC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 87.04% and 0.46%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Emergent Biosolutions (EBS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: BIIB's Q4 Results, EBS and BPMC Offer Updates
by Zacks Equity Research
Earnings results from Biogen (BIIB) and updates from EBS are the key highlights from the biotech sector during the past week.
Emergent Biosolutions (EBS) Moves 12.5% Higher: Will This Strength Last?
by Zacks Equity Research
Emergent Biosolutions (EBS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -27.94% and 65.46%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?
Is ALPS International Sector Dividend Dogs ETF (IDOG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IDOG
Emergent (EBS) to Start Restructuring Plan, Lays Off 5% Workforce
by Zacks Equity Research
Once this restructuring activity is completed, Emergent BioSolutions (EBS) expects to result in annualized savings of over $60 million. It also slightly raised its total revenue guidance for 2022.